GB Sciences, Inc.

57 articles with GB Sciences, Inc.

• GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations

  7/17/2019

  In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars.

• GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

  6/11/2019

  Oral thin films provide a convenient and accurate delivery system with increased bioavailability of cannabis active ingredients for patients

• GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies

  5/28/2019

  GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients

• GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center

  4/16/2019

  Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients.

• Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times

  4/2/2019

  GB Sciences, Inc. announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference, April 2, at 4:40pm.

• GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients

  3/28/2019

  What consumers see is not what they get: Study finds almost no chemical diversity in Nevada's cannabis varieties

• In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility

  3/26/2019

  With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana.

• GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

  3/19/2019

  Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy

• GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue

  3/12/2019

  LSU AgCenter issued the following statement on Friday, March 8th.

• GB Sciences Completes Harvest of First Cannabis Crop in Partnership with The Louisiana State University Agricultural Research Center

  1/16/2019

  Nationally recognized collaboration with the Louisiana State University Agricultural Center

• GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars

  12/12/2018

  Additionally, this first crop provides important seeds and genetics for future crops

• Exploring the Lesser Cannabinoids - The Happy Accident of CBN

  12/12/2018

  The following is from GB Sciences, Inc.'s (OTCQB: GBLX) "The Cannabis Brain Nurse," Meredith Patterson RN, BSN, CRRN: With or without a working knowledge of cannabis, most dispensary consumers have a speaking acquaintance with the compounds THC and CBD. 

• GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases

  12/7/2018

  GB Sciences, Inc. (OTCQB: GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC.

• GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor

  11/27/2018

  Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure.

• GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles

  11/20/2018

  First of their kind, myrcene nanoparticles are central to a novel, time-released therapeutic for neuropathic pain

• GB Sciences Expands into the Oklahoma Medical Cannabis Market

  11/14/2018

  GB Sciences' signs a letter of binding agreement with 4EVERGRN in its first out-of-state licensing deal. 

• More From Meredith Patterson, GB Sciences' Brain Nurse, As She Examines the Workings of CBD

  11/14/2018

  Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences.

• Meredith Patterson, GB Sciences' Brain Nurse, Examines the Workings of CBD

  11/6/2018

  Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences.

• GB Sciences Sponsors "2018 Innovation In Medical Cannabis Therapies" Symposium

  11/1/2018

  On November 9th, an international medical cannabis symposium, led by Dr. Andrea Small-Howard, will be held in Las Vegas, NV.

• GB Sciences' Brain Nurse Explores the New and Exciting World of Medical Cannabis

  10/25/2018

  Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse" writes a series of popular science cannabis blogs for GB Sciences.